Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917783304> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W1917783304 endingPage "797" @default.
- W1917783304 startingPage "797" @default.
- W1917783304 abstract "Estrogen plays a role in the activation of systemic lupus erythematosus (SLE) and in upregulating intracellular signals by binding to the estrogen receptor(s). Fulvestrant (Faslodex, AstraZeneca Pharmaceuticals, Wilmington, DE, USA), an estrogen selective receptor downregulator, competes for receptor binding in vitro and inhibits estrogen action in target cells. We evaluated the efficacy, side effects, and expression of T cell activation markers, following the administration of fulvestrant or placebo to premenopausal patients with SLE.Twenty women with moderate SLE Disease Activity Index (SLEDAI; 7.87 +/- 3.7) were enrolled. They were premenopausal with regular menstrual cycles and not taking exogenous hormones. The study was double-blind and placebo-controlled. Ten patients received 250 mg fulvestrant intramuscularly for 12 months, and 10 received the placebo. All were observed monthly and 3 months after final fulvestrant/placebo injection. Measures studied were monthly SLEDAI scores, routine and serologic markers for lupus, and serum concentrations of estrogen and fulvestrant. Expression of T cell calcineurin and CD154 mRNA in peripheral T cells was measured by polymerase chain reaction. Medications the patients were taking were recorded each visit. Bone density was obtained at baseline and at visit 12.Sixteen patients completed the 15-month study, 8 from each group. SLEDAI improved significantly in the fulvestrant group at both 12 months (p = 0.02) and 15 months (p = 0.002), but serologic markers, routine laboratory tests, and bone density did not. Serum estrogen levels were higher in the fulvestrant group and dropped when fulvestrant was discontinued; these differences were not statistically significant. Medications for therapy of lupus to the fulvestrant group were reduced, whereas the placebo group medications were unchanged or increased. Comparison of relative values at individual timepoints revealed significantly lower median values for the T cell activation markers CD154 (p < 0.001) and calcineurin (p = 0.013) in the fulvestrant arm.Blocking estrogen receptors in vivo by an estrogen selective receptor downregulator could be considered as a new and relatively safe therapeutic approach in the management of SLE patients with moderately active disease for the 1-year study period." @default.
- W1917783304 created "2016-06-24" @default.
- W1917783304 creator A5051037095 @default.
- W1917783304 creator A5058830197 @default.
- W1917783304 creator A5059418271 @default.
- W1917783304 creator A5063673325 @default.
- W1917783304 creator A5086827787 @default.
- W1917783304 date "2008-05-01" @default.
- W1917783304 modified "2023-09-23" @default.
- W1917783304 title "Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial." @default.
- W1917783304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18381791" @default.
- W1917783304 hasPublicationYear "2008" @default.
- W1917783304 type Work @default.
- W1917783304 sameAs 1917783304 @default.
- W1917783304 citedByCount "17" @default.
- W1917783304 countsByYear W19177833042013 @default.
- W1917783304 countsByYear W19177833042016 @default.
- W1917783304 countsByYear W19177833042017 @default.
- W1917783304 countsByYear W19177833042018 @default.
- W1917783304 countsByYear W19177833042019 @default.
- W1917783304 countsByYear W19177833042021 @default.
- W1917783304 countsByYear W19177833042022 @default.
- W1917783304 countsByYear W19177833042023 @default.
- W1917783304 crossrefType "journal-article" @default.
- W1917783304 hasAuthorship W1917783304A5051037095 @default.
- W1917783304 hasAuthorship W1917783304A5058830197 @default.
- W1917783304 hasAuthorship W1917783304A5059418271 @default.
- W1917783304 hasAuthorship W1917783304A5063673325 @default.
- W1917783304 hasAuthorship W1917783304A5086827787 @default.
- W1917783304 hasConcept C121608353 @default.
- W1917783304 hasConcept C126322002 @default.
- W1917783304 hasConcept C134018914 @default.
- W1917783304 hasConcept C142724271 @default.
- W1917783304 hasConcept C143998085 @default.
- W1917783304 hasConcept C204787440 @default.
- W1917783304 hasConcept C27081682 @default.
- W1917783304 hasConcept C2777164284 @default.
- W1917783304 hasConcept C2780482068 @default.
- W1917783304 hasConcept C530470458 @default.
- W1917783304 hasConcept C71924100 @default.
- W1917783304 hasConcept C84606932 @default.
- W1917783304 hasConcept C90924648 @default.
- W1917783304 hasConceptScore W1917783304C121608353 @default.
- W1917783304 hasConceptScore W1917783304C126322002 @default.
- W1917783304 hasConceptScore W1917783304C134018914 @default.
- W1917783304 hasConceptScore W1917783304C142724271 @default.
- W1917783304 hasConceptScore W1917783304C143998085 @default.
- W1917783304 hasConceptScore W1917783304C204787440 @default.
- W1917783304 hasConceptScore W1917783304C27081682 @default.
- W1917783304 hasConceptScore W1917783304C2777164284 @default.
- W1917783304 hasConceptScore W1917783304C2780482068 @default.
- W1917783304 hasConceptScore W1917783304C530470458 @default.
- W1917783304 hasConceptScore W1917783304C71924100 @default.
- W1917783304 hasConceptScore W1917783304C84606932 @default.
- W1917783304 hasConceptScore W1917783304C90924648 @default.
- W1917783304 hasIssue "5" @default.
- W1917783304 hasLocation W19177833041 @default.
- W1917783304 hasOpenAccess W1917783304 @default.
- W1917783304 hasPrimaryLocation W19177833041 @default.
- W1917783304 hasRelatedWork W1481419339 @default.
- W1917783304 hasRelatedWork W1773961151 @default.
- W1917783304 hasRelatedWork W1939532313 @default.
- W1917783304 hasRelatedWork W1974187993 @default.
- W1917783304 hasRelatedWork W2010293505 @default.
- W1917783304 hasRelatedWork W2018996303 @default.
- W1917783304 hasRelatedWork W2019743324 @default.
- W1917783304 hasRelatedWork W2079148101 @default.
- W1917783304 hasRelatedWork W2092998826 @default.
- W1917783304 hasRelatedWork W2098214350 @default.
- W1917783304 hasRelatedWork W2113864921 @default.
- W1917783304 hasRelatedWork W2118955900 @default.
- W1917783304 hasRelatedWork W2131578833 @default.
- W1917783304 hasRelatedWork W2131917724 @default.
- W1917783304 hasRelatedWork W2141455950 @default.
- W1917783304 hasRelatedWork W2146203649 @default.
- W1917783304 hasRelatedWork W2159203244 @default.
- W1917783304 hasRelatedWork W2320201010 @default.
- W1917783304 hasRelatedWork W2442430121 @default.
- W1917783304 hasRelatedWork W250985495 @default.
- W1917783304 hasVolume "35" @default.
- W1917783304 isParatext "false" @default.
- W1917783304 isRetracted "false" @default.
- W1917783304 magId "1917783304" @default.
- W1917783304 workType "article" @default.